KRAS and colonic neoplasm: TAK1 inhibition suppresses inflammation and fibrosis in the colon, kidney, and lung30,35,36 and inhibits the in vivo growth of KRAS-mutated colon cancer cells and pro-survival signaling in breast cancer cells37,38.